Cipla gets 4 USFDA observations for Patalganga facility
New Delhi: Drug maker Cipla recently informed that the United States Food and Drug Administration (USFDA) conducted a routine cGMP (current Good Manufacturing Practice) inspection for both formulations and active pharmaceutical ingredients (APIs) at the company's manufacturing facility in Patalganga. The inspection ended with 4 observations.
The inspection of the facilities was conducted from 4th to 13 November 2019.
Also Read: Cipla gets 7 USFDA observations for Bengaluru API unit
"The inspection ended with 4 observations, none of which were a repeat or related to data integrity," Cipla said in a filing.
"The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time, " the company added.
Headquartered in Mumbai, Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
Read Also: Cipla gets 12 USFDA observations for Goa facility